

					
						November 30, 2017 - By Vivian Currie
Among 3 analysts covering CytomX Therapeutics (NASDAQ:CTMX), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. CytomX Therapeutics had 4 analyst reports since November 2, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Cowen & Co given on Monday, November 2. Oppenheimer initiated CytomX Therapeutics, Inc. (NASDAQ:CTMX) on Monday, November 2 with “Outperform” rating. The rating was downgraded by Oppenheimer on Tuesday, January 3 to “Perform”. Jefferies initiated the shares of CTMX in report on Monday, November 2 with “Buy” rating. See CytomX Therapeutics, Inc. (NASDAQ:CTMX) latest ratings:Community Trust & Investment Co increased Bp Plc Spons Adr (BP) stake by 53.32% reported in 2017Q2 SEC filing. Community Trust & Investment Co acquired 118,040 shares as Bp Plc Spons Adr (BP)’s stock rose 10.53%. The Community Trust & Investment Co holds 339,410 shares with $11.76M value, up from 221,370 last quarter. Bp Plc Spons Adr now has $128.77 billion valuation. The stock increased 0.19% or $0.08 during the last trading session, reaching $39.78. About 4.28 million shares traded. BP p.l.c. (NYSE:BP) has risen 15.51% since November 30, 2016 and is uptrending. It has underperformed by 1.19% the S&P500.CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical firm in the United States. The company has market cap of $797.75 million. The firm develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. It currently has negative earnings. The Company’s other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188.The stock increased 2.01% or $0.41 during the last trading session, reaching $20.77. About 104,976 shares traded. CytomX Therapeutics, Inc. (NASDAQ:CTMX) has risen 50.10% since November 30, 2016 and is uptrending. It has outperformed by 33.40% the S&P500.Among 29 analysts covering BP (NYSE:BP), 19 have Buy rating, 2 Sell and 8 Hold. Therefore 66% are positive. BP had 50 analyst reports since July 24, 2015 according to SRatingsIntel. On Tuesday, August 29 the stock rating was maintained by Jefferies with “Hold”. The rating was initiated by Nomura with “Neutral” on Friday, March 18. The rating was upgraded by Argus Research to “Buy” on Friday, July 31. On Friday, September 11 the stock rating was downgraded by Jefferies to “Hold”. The stock has “Buy” rating by J.P. Morgan on Monday, June 12. As per Wednesday, July 29, the company rating was maintained by BNP Paribas. The company was upgraded on Thursday, December 1 by Credit Suisse. The stock has “Buy” rating by Liberum Capital on Tuesday, September 15. The stock has “Buy” rating by Piper Jaffray on Thursday, August 24. UBS downgraded the shares of BP in report on Thursday, October 20 to “Neutral” rating.Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



(adsbygoogle = window.adsbygoogle || []).push({});
